Is there a role for erythropoietin in cardiovascular disease?

Bibliography

• Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357:1121-35
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Petrie MC, Murdoch DR, Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998;19(Suppl P):9-16
   Google Scholar
• Schuster SJ, Koury ST, Bohler M, Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br J Haematol 1992;81:153-9
   PubMed Web of Science ®Google Scholar
• Anagnostou A, Liu Z, Steiner M, Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974-39
   PubMed Web of Science ®Google Scholar
• Wu H, Liu X, Jaenisch R, Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995;83:59-67
   PubMed Web of Science ®Google Scholar
• Tilbrook PA, Klinken SP. Erythropoietin and erythropoietin receptor. Growth Factors 1999;17:25-35
   PubMed Web of Science ®Google Scholar
• Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1964-977
   Google Scholar
• Anagnostou A, Lee ES, Kessimian N, Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-82
   PubMed Web of Science ®Google Scholar
• Akimoto T, Kusano E, Inaba T, Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 2000;58:269-82
   PubMed Web of Science ®Google Scholar
• Tramontano AF, Muniyappa R, Black AD, Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308:990-4
   PubMed Web of Science ®Google Scholar
• Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 2002;277:29355-58
   PubMed Web of Science ®Google Scholar
• Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71:524-27
   PubMed Web of Science ®Google Scholar
• Dame C, Fahnenstich H, Freitag P, Erythropoietin mRNA in human fetal and neonatal tissue. Blood 1998;92:3218-25
   PubMed Web of Science ®Google Scholar
• Gabrilove J. Overview: erythropoiesis, anemia, and the impact of erythropoietin. Semin Hematol 2000;37(Suppl 6):1-3
   PubMedGoogle Scholar
• Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008;264:405-32
   PubMed Web of Science ®Google Scholar
• Ammarguellat F, Llovera M, Kelly PA, Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2001;284(4):1031-8
   PubMed Web of Science ®Google Scholar
• Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-38
   PubMed Web of Science ®Google Scholar
• Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005;6:484-94
   PubMed Web of Science ®Google Scholar
• Buemi M, Cavallaro E, Floccari F, The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003;62:228-36
   PubMed Web of Science ®Google Scholar
• Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90-5
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell intergrity. Br J Pharmacol 2007;150:839-50
   PubMed Web of Science ®Google Scholar
• Burger D, Xenocostas A, Feng QP. Molecular basis of cardioprotection by erythropoietin. Curr Mol Pharm 2009;2:56-69
   PubMedGoogle Scholar
• Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurogenerative disease. Prog Neurobiol 2005;75:207-46
   PubMed Web of Science ®Google Scholar
• Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004;25:577-83
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973-9
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Akt1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-xL and caspase 1, 3 and 9. Exp Cell Res 2004;296:196-207
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Lin SH, Kang JQ, Erythropoietin caspase 1,3 and 8. J Neurosci Res 2003;71:659-69
   PubMed Web of Science ®Google Scholar
• Hirata A, Minamino T, Asanuma H, Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 2005;19:33-40
   PubMed Web of Science ®Google Scholar
• Burger D, Lei M, Geoghegan-Morphet N, Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 2006;72:51-9
   PubMed Web of Science ®Google Scholar
• Burger D, Xiang H, Hammoud L, Role of heme oxygenase-1 in the cardioprotective effects of erythropoietin during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2009;296:H84-93
   PubMed Web of Science ®Google Scholar
• Burger D, Xiang FL, Hammoud L, Erythropoietin protects the heart from ventricular arrhythmia during ischemia and reperfusion via neuronal nitric-oxide synthase. J Pharmacol Exp Ther 2009;329:900-7
   PubMed Web of Science ®Google Scholar
• Li F, Chong ZZ, Maiese K. Cell life versus cell longevity: the mysteries surrounding the NAD+ precursor nicotinamide. Curr Med Chem 2006;13:883-95
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Shang YC. “Sly as a FOXO”: new paths with forkhead signalling in the brain. Curr Neurovasc Res 2007;4:295-302
   PubMed Web of Science ®Google Scholar
• Asaumi Y, Kagaya Y, Takeda M, Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007;115:2022-32
   PubMed Web of Science ®Google Scholar
• Suzuki N, Ohneda O, Takahashi S, Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002;100(7):2279-88
   PubMed Web of Science ®Google Scholar
• Wu H, Lee SH, Gao J, Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999;126:3597-605
   PubMed Web of Science ®Google Scholar
• Ashley RA, Dubuque SH, Dvorak B, Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr Res 2002;51:472-8
   PubMed Web of Science ®Google Scholar
• Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995;47:740-5
   PubMed Web of Science ®Google Scholar
• Lipsic E, Schoemaker RG, van der Meer P, Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-7
   PubMed Web of Science ®Google Scholar
• Calvillo L, Latini R, Kajstura J, Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-06
   PubMed Web of Science ®Google Scholar
• Nishihara M, Miura T, Miki T, Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3beta. Am J Physiol 2006;291:H748-55
   PubMed Web of Science ®Google Scholar
• Moon C, Krawczyk M, Ahn D, Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003;100:11612-17
   PubMed Web of Science ®Google Scholar
• Cai Z, Manalo DJ, Wei G, Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003;108:79-85
   PubMed Web of Science ®Google Scholar
• Hirata A, Minamino T, Asanuma H, Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006;48:176-84
   Google Scholar
• Parsa CJ, Matsumoto A, Kim J, A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007
   PubMed Web of Science ®Google Scholar
• Lipsic E, Westenbrink BD, van der Meer P, Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22-9
   PubMed Web of Science ®Google Scholar
• Prunier F, Pfister O, Hadri L, Delayed erythropoietin therapy reduces post- MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007;292:H522-29
   PubMed Web of Science ®Google Scholar
• Gao E, Boucher M, Chuporun JK, Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 2007;293:H60-8
   PubMed Web of Science ®Google Scholar
• van der Meer P, Lipsic E, Henning RH, Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-33
   PubMed Web of Science ®Google Scholar
• Westenbrink BD, Lipsic E, van der Meer P, Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;28:2018-27
   PubMed Web of Science ®Google Scholar
• Moon C, Krawzcyk M, Paik D, Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 2005;19:243-50
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, de GK, Spandau JM, Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921-6
   PubMed Web of Science ®Google Scholar
• Westenbrink BD, Oeseburg H, Kleijn L, Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther 2008;22:265-74
   PubMed Web of Science ®Google Scholar
• Jaquet K, Krause K, Tawakol-Khodai M, Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326-33
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, De Groot K, Spandau JM, Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921-26
   PubMed Web of Science ®Google Scholar
• Hirata A, Minamino T, Asanuma H, Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006;48:176-84
   Google Scholar
• Toma C, Letts DP, Tanabe M, Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. J Mol Cell Cardiol 2007;43:130-36
   PubMed Web of Science ®Google Scholar
• Westenbrink BD, Oeseburg H, Kleijn L, Erythropoietin stimulates normal endothelial progenitor cell mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther 2008;22(4):265-74
   PubMed Web of Science ®Google Scholar
• George J, Goldstein E, Abashidze A, Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 2005;68:299-306
   PubMed Web of Science ®Google Scholar
• Li Y, Takemura G, Okada H, Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006;71:684-94
   PubMed Web of Science ®Google Scholar
• Coleman TR, Westenfelder C, Togel FE, Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Nat Acad Sci USA 2006;103:5965-70
   PubMed Web of Science ®Google Scholar
• Leist M, Ghezzi P, Grasso G, Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42
   PubMed Web of Science ®Google Scholar
• Namiuchi S, Kagaya Y, Ohta J, High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005;45:1406-12
   PubMed Web of Science ®Google Scholar
• Lipsic E, van der Meer P, Voors AA, A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-41
   PubMed Web of Science ®Google Scholar
• Liem A, van de Woestijne AP, Bruijns E, Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 2009;131:285-7
   PubMed Web of Science ®Google Scholar
• Ferrario M, Massa M, Rosti V, Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J 2007;28:1805-13
   PubMed Web of Science ®Google Scholar
• Mudalagiri NR, Mocanu MM, Di Salvo C, Erythropoietin protects the human myocardium against hypoxia-reoxygenation injury via PI3-kinase and ERK1/2 activation. Br J Pharmacol 2008;153:46-50
   Google Scholar
• Belonje A, Voors A, van Gilst W, Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 2008;155:817-22
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14
   PubMed Web of Science ®Google Scholar
• Phrommintikul A, Haas SJ, Elsik M, Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8
   PubMed Web of Science ®Google Scholar
• Shibata J, Hasegawa J, Siemens HJ, Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. Blood 2003;101:4416-22
   PubMed Web of Science ®Google Scholar
• Stohlawetz PJ, Dzirlo L, Hergovich N, Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-89
   PubMed Web of Science ®Google Scholar
• Noguchi K, Yamashiro S, Matsuzaki T, Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits. Br J Pharmacol 2001;133:395-405
   PubMed Web of Science ®Google Scholar
• Tang YD, Rinder HM, Katz SD. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo controlled randomized trial. Am Heart J 2007;154:494, e1-7
   PubMedGoogle Scholar
• Coleman TR, Westenfelder C, Togel FE, Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Nat Acad Sci USA 2006;103:5965-70
   PubMed Web of Science ®Google Scholar
• Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 2004;10:S5-9
   PubMed Web of Science ®Google Scholar
• Van der Meer P, Voors AA, Lipsic E, Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004;44:63-7
   PubMed Web of Science ®Google Scholar
• Silverberg D. Outcomes of anemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003;18:ii7-ii12
   PubMedGoogle Scholar
• Ishani A, Weinhandl E, Zhao Z, Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005;45:391-9
   PubMed Web of Science ®Google Scholar
• de Silva R, Rigby AS, Witte KK, Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 2006;98:391-8
   PubMed Web of Science ®Google Scholar
• Nanas J, Matsouka C, Karageorgopoulos D, Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48:2485-9
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Iaina A, Anemia, chronic renal disease and congestive heart failure-the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006;38:295-310
   PubMed Web of Science ®Google Scholar
• Cleland JG, Coletta AP, Clark AL, Clinical trials update from the European Society of Cardiology Heart Failure Meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail 2005;7:937-9
   PubMed Web of Science ®Google Scholar
• Palazzuoli A, Silverberg D, Iovine F, Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006;152:1096e9-e15
   Google Scholar
• Ponikowski P, Anker SD, Szachniewicz J, Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007;49:753-62
   PubMed Web of Science ®Google Scholar
• Ghali JK, Anand IS, Abraham WT, Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008;117:526-35
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Randomized, double-blind, placebo controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007;28:2208-16
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Sheps D, The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Blum M, The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transpl 2003;18:141-6
   PubMed Web of Science ®Google Scholar
• George J, Patal S, Wexler D, Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005;165:1304-09
   PubMed Web of Science ®Google Scholar
• Mancini DM, Katz SD, Lang CC, Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-9
   PubMed Web of Science ®Google Scholar
• van der Meer P, Groenveld HF, Januzzi JL, Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009;95:1309-14
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84
   PubMed Web of Science ®Google Scholar
• Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp). Available from: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm054721.htm[last accessed December 2009]
   Google Scholar
• Provenzano R, Besarab A, Macdougall IC, The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a Phase II study. Clin Nephrol 2007;67:306-17
   PubMed Web of Science ®Google Scholar